Industry Research Reports
Global Rare Neurodegenerative Disease Treatment Market Research Report 2025
Industry: Pharma & Healthcare
Published Date: 2025-02-21
Pages: 84 Pages
Report ld: 4125921
Request Sample
Customized Report
- Description
- Table of Contents
- Table of Figures
- Related Reports
PDF Download
- Description
- Table of Contents
- Table of Figures
- Related Reports
- PDF Download
Rare Neurodegenerative Disease Treatment Market Size(US$)
CAGR 2025-2031
6%
Market Size,2031
USD 93,810
Million
Market Snapshot
Source: Secondary research, interviews with experts, and QYResearch analysis
The global market for Rare Neurodegenerative Disease Treatment was valued at US$ 62750 million in the year 2024 and is projected to reach a revised size of US$ 93810 million by 2031, growing at a CAGR of 6.0% during the forecast period.
Neurodegenerative diseases largely refer to incremental damage to nerve cells in different parts of the body. These ailments, including Alzheimer’s disease, Parkinson’s disease, ADHD, and ALS, can result in loss of memory and cognitive control. While cures for such conditions are very limited, over the years, the pharmaceutical industry has released a number of treatment offerings to minimize the symptoms of neurodegenerative diseases.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
REPORT SCOPE
This report aims to provide a comprehensive presentation of the global market for Rare Neurodegenerative Disease Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Rare Neurodegenerative Disease Treatment.
The Rare Neurodegenerative Disease Treatment market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Rare Neurodegenerative Disease Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Rare Neurodegenerative Disease Treatment manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
Bayer
GlaxoSmithKline
Hoffmann-La Roche
Allergan
Merck KGaA
Johnson and Johnson
Pfizer
Novartis
Sanofi
Teva Pharmaceuticals
Segment by Type
Neurotransmitter Agents
Neuroprotective Agents
Biologics
Others
Segment by Application
Amyotrophic Lateral Sclerosis (ALS)
Attention Deficit Hyperactivity Disorder (ADHD)
Alzheimer’s Disease
Parkinson’s Disease
Others
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Middle East and Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Rare Neurodegenerative Disease Treatment manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Rare Neurodegenerative Disease Treatment in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
QYRESEARCH'S STRENGTHS
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:
We identify regional market threats and growth prospects to guide your overseas layout.
We adjust product portfolios in line with local consumption habits.
We unpack rivals’ operation strategies for scattered and highly concentrated industries.
We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.
We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.
Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.
We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.
All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.
We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.
TABLE OF CONTENTS
1 Rare Neurodegenerative Disease Treatment Market Overview
1.1 Product Definition
1.2 Rare Neurodegenerative Disease Treatment by Type
1.2.1 Global Rare Neurodegenerative Disease Treatment Market Value Comparison by Type (2024 VS 2031)
1.2.2 Neurotransmitter Agents
1.2.3 Neuroprotective Agents
1.2.4 Biologics
1.2.5 Others
1.3 Rare Neurodegenerative Disease Treatment by Application
1.3.1 Global Rare Neurodegenerative Disease Treatment Market Value by Application (2024 VS 2031)
1.3.2 Amyotrophic Lateral Sclerosis (ALS)
1.3.3 Attention Deficit Hyperactivity Disorder (ADHD)
1.3.4 Alzheimer’s Disease
1.3.5 Parkinson’s Disease
1.3.6 Others
1.4 Global Rare Neurodegenerative Disease Treatment Market Size Estimates and Forecasts
1.4.1 Global Rare Neurodegenerative Disease Treatment Revenue 2020-2031
1.4.2 Global Rare Neurodegenerative Disease Treatment Sales 2020-2031
1.4.3 Global Rare Neurodegenerative Disease Treatment Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Rare Neurodegenerative Disease Treatment Market Competition by Manufacturers
2.1 Global Rare Neurodegenerative Disease Treatment Sales Market Share by Manufacturers (2020-2025)
2.2 Global Rare Neurodegenerative Disease Treatment Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Rare Neurodegenerative Disease Treatment Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Rare Neurodegenerative Disease Treatment, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Rare Neurodegenerative Disease Treatment, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Rare Neurodegenerative Disease Treatment, Product Type & Application
2.7 Global Key Manufacturers of Rare Neurodegenerative Disease Treatment, Date of Enter into This Industry
2.8 Global Rare Neurodegenerative Disease Treatment Market Competitive Situation and Trends
2.8.1 Global Rare Neurodegenerative Disease Treatment Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Rare Neurodegenerative Disease Treatment Players Market Share by Revenue
2.8.3 Global Rare Neurodegenerative Disease Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Rare Neurodegenerative Disease Treatment Market Scenario by Region
3.1 Global Rare Neurodegenerative Disease Treatment Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Rare Neurodegenerative Disease Treatment Sales by Region: 2020-2031
3.2.1 Global Rare Neurodegenerative Disease Treatment Sales by Region: 2020-2025
3.2.2 Global Rare Neurodegenerative Disease Treatment Sales by Region: 2026-2031
3.3 Global Rare Neurodegenerative Disease Treatment Revenue by Region: 2020-2031
3.3.1 Global Rare Neurodegenerative Disease Treatment Revenue by Region: 2020-2025
3.3.2 Global Rare Neurodegenerative Disease Treatment Revenue by Region: 2026-2031
3.4 North America Rare Neurodegenerative Disease Treatment Market Facts & Figures by Country
3.4.1 North America Rare Neurodegenerative Disease Treatment Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Rare Neurodegenerative Disease Treatment Sales by Country (2020-2031)
3.4.3 North America Rare Neurodegenerative Disease Treatment Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Rare Neurodegenerative Disease Treatment Market Facts & Figures by Country
3.5.1 Europe Rare Neurodegenerative Disease Treatment Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Rare Neurodegenerative Disease Treatment Sales by Country (2020-2031)
3.5.3 Europe Rare Neurodegenerative Disease Treatment Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Rare Neurodegenerative Disease Treatment Market Facts & Figures by Region
3.6.1 Asia Pacific Rare Neurodegenerative Disease Treatment Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Rare Neurodegenerative Disease Treatment Sales by Region (2020-2031)
3.6.3 Asia Pacific Rare Neurodegenerative Disease Treatment Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Rare Neurodegenerative Disease Treatment Market Facts & Figures by Country
3.7.1 Latin America Rare Neurodegenerative Disease Treatment Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Rare Neurodegenerative Disease Treatment Sales by Country (2020-2031)
3.7.3 Latin America Rare Neurodegenerative Disease Treatment Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Rare Neurodegenerative Disease Treatment Market Facts & Figures by Country
3.8.1 Middle East and Africa Rare Neurodegenerative Disease Treatment Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Rare Neurodegenerative Disease Treatment Sales by Country (2020-2031)
3.8.3 Middle East and Africa Rare Neurodegenerative Disease Treatment Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Rare Neurodegenerative Disease Treatment Sales by Type (2020-2031)
4.1.1 Global Rare Neurodegenerative Disease Treatment Sales by Type (2020-2025)
4.1.2 Global Rare Neurodegenerative Disease Treatment Sales by Type (2026-2031)
4.1.3 Global Rare Neurodegenerative Disease Treatment Sales Market Share by Type (2020-2031)
4.2 Global Rare Neurodegenerative Disease Treatment Revenue by Type (2020-2031)
4.2.1 Global Rare Neurodegenerative Disease Treatment Revenue by Type (2020-2025)
4.2.2 Global Rare Neurodegenerative Disease Treatment Revenue by Type (2026-2031)
4.2.3 Global Rare Neurodegenerative Disease Treatment Revenue Market Share by Type (2020-2031)
4.3 Global Rare Neurodegenerative Disease Treatment Price by Type (2020-2031)
5 Segment by Application
5.1 Global Rare Neurodegenerative Disease Treatment Sales by Application (2020-2031)
5.1.1 Global Rare Neurodegenerative Disease Treatment Sales by Application (2020-2025)
5.1.2 Global Rare Neurodegenerative Disease Treatment Sales by Application (2026-2031)
5.1.3 Global Rare Neurodegenerative Disease Treatment Sales Market Share by Application (2020-2031)
5.2 Global Rare Neurodegenerative Disease Treatment Revenue by Application (2020-2031)
5.2.1 Global Rare Neurodegenerative Disease Treatment Revenue by Application (2020-2025)
5.2.2 Global Rare Neurodegenerative Disease Treatment Revenue by Application (2026-2031)
5.2.3 Global Rare Neurodegenerative Disease Treatment Revenue Market Share by Application (2020-2031)
5.3 Global Rare Neurodegenerative Disease Treatment Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Bayer
6.1.1 Bayer Company Information
6.1.2 Bayer Description and Business Overview
6.1.3 Bayer Rare Neurodegenerative Disease Treatment Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Bayer Rare Neurodegenerative Disease Treatment Product Portfolio
6.1.5 Bayer Recent Developments/Updates
6.2 GlaxoSmithKline
6.2.1 GlaxoSmithKline Company Information
6.2.2 GlaxoSmithKline Description and Business Overview
6.2.3 GlaxoSmithKline Rare Neurodegenerative Disease Treatment Sales, Revenue and Gross Margin (2020-2025)
6.2.4 GlaxoSmithKline Rare Neurodegenerative Disease Treatment Product Portfolio
6.2.5 GlaxoSmithKline Recent Developments/Updates
6.3 Hoffmann-La Roche
6.3.1 Hoffmann-La Roche Company Information
6.3.2 Hoffmann-La Roche Description and Business Overview
6.3.3 Hoffmann-La Roche Rare Neurodegenerative Disease Treatment Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Hoffmann-La Roche Rare Neurodegenerative Disease Treatment Product Portfolio
6.3.5 Hoffmann-La Roche Recent Developments/Updates
6.4 Allergan
6.4.1 Allergan Company Information
6.4.2 Allergan Description and Business Overview
6.4.3 Allergan Rare Neurodegenerative Disease Treatment Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Allergan Rare Neurodegenerative Disease Treatment Product Portfolio
6.4.5 Allergan Recent Developments/Updates
6.5 Merck KGaA
6.5.1 Merck KGaA Company Information
6.5.2 Merck KGaA Description and Business Overview
6.5.3 Merck KGaA Rare Neurodegenerative Disease Treatment Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Merck KGaA Rare Neurodegenerative Disease Treatment Product Portfolio
6.5.5 Merck KGaA Recent Developments/Updates
6.6 Johnson and Johnson
6.6.1 Johnson and Johnson Company Information
6.6.2 Johnson and Johnson Description and Business Overview
6.6.3 Johnson and Johnson Rare Neurodegenerative Disease Treatment Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Johnson and Johnson Rare Neurodegenerative Disease Treatment Product Portfolio
6.6.5 Johnson and Johnson Recent Developments/Updates
6.7 Pfizer
6.7.1 Pfizer Company Information
6.7.2 Pfizer Description and Business Overview
6.7.3 Pfizer Rare Neurodegenerative Disease Treatment Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Pfizer Rare Neurodegenerative Disease Treatment Product Portfolio
6.7.5 Pfizer Recent Developments/Updates
6.8 Novartis
6.8.1 Novartis Company Information
6.8.2 Novartis Description and Business Overview
6.8.3 Novartis Rare Neurodegenerative Disease Treatment Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Novartis Rare Neurodegenerative Disease Treatment Product Portfolio
6.8.5 Novartis Recent Developments/Updates
6.9 Sanofi
6.9.1 Sanofi Company Information
6.9.2 Sanofi Description and Business Overview
6.9.3 Sanofi Rare Neurodegenerative Disease Treatment Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Sanofi Rare Neurodegenerative Disease Treatment Product Portfolio
6.9.5 Sanofi Recent Developments/Updates
6.10 Teva Pharmaceuticals
6.10.1 Teva Pharmaceuticals Company Information
6.10.2 Teva Pharmaceuticals Description and Business Overview
6.10.3 Teva Pharmaceuticals Rare Neurodegenerative Disease Treatment Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Teva Pharmaceuticals Rare Neurodegenerative Disease Treatment Product Portfolio
6.10.5 Teva Pharmaceuticals Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Rare Neurodegenerative Disease Treatment Industry Chain Analysis
7.2 Rare Neurodegenerative Disease Treatment Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Rare Neurodegenerative Disease Treatment Production Mode & Process Analysis
7.4 Rare Neurodegenerative Disease Treatment Sales and Marketing
7.4.1 Rare Neurodegenerative Disease Treatment Sales Channels
7.4.2 Rare Neurodegenerative Disease Treatment Distributors
7.5 Rare Neurodegenerative Disease Treatment Customer Analysis
8 Rare Neurodegenerative Disease Treatment Market Dynamics
8.1 Rare Neurodegenerative Disease Treatment Industry Trends
8.2 Rare Neurodegenerative Disease Treatment Market Drivers
8.3 Rare Neurodegenerative Disease Treatment Market Challenges
8.4 Rare Neurodegenerative Disease Treatment Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
TABLE OF FIGURES
List of Tables
List of Figures
KEY QUESTIONS ADDRESSED BY THE REPORT
Related Reports
Rare Neurodegenerative Disease Treatment- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Rare Neurodegenerative Disease Treatment was estimated to be worth US$ 66140 million in 2025 and is projected to reach US$ 98880 million, growing at a CAGR of 6.0% from 2026 to 2032.
Published Date: 2026-07-09
Pages: 129
USD 3950.00
(Single User License)
Global Rare Neurodegenerative Disease Treatment Market Research Report 2026
The global Rare Neurodegenerative Disease Treatment market was valued at US$ 66140 million in 2025 and is anticipated to reach US$ 98880 million by 2032, at a CAGR of 6.0% from 2026 to 2032.
Published Date: 2026-04-21
Pages: 116
USD 2900.00
(Single User License)
Global Rare Neurodegenerative Disease Treatment Market Outlook, In‑Depth Analysis & Forecast to 2031
The global Rare Neurodegenerative Disease Treatment market is projected to grow from US$ 62750 million in 2024 to US$ 93810 million by 2031, at a CAGR of 6.0% (2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Published Date: 2025-10-25
Pages: 138
USD 4900.00
(Single User License)
Rare Neurodegenerative Disease Treatment- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Rare Neurodegenerative Disease Treatment was estimated to be worth US$ 62750 million in 2024 and is forecast to a readjusted size of US$ 93810 million by 2031 with a CAGR of 6.0% during the forecast period 2025-2031.
Published Date: 2025-02-21
Pages: 109
USD 3950.00
(Single User License)
Global Rare Neurodegenerative Disease Treatment Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Rare Neurodegenerative Disease Treatment market size was US$ 62750 million in 2024 and is forecast to a readjusted size of US$ 93810 million by 2031 with a CAGR of 6.0% during the forecast period 2025-2031.
Published Date: 2025-02-21
Pages: 77
USD 4250.00
(Single User License)
Global Rare Neurodegenerative Disease Treatment Market Insights, Forecast to 2030
Neurodegenerative diseases largely refer to incremental damage to nerve cells in different parts of the body. These ailments, including Alzheimer’s disease, Parkinson’s disease, ADHD, and ALS, can result in loss of memory and cognitive control. While cures for such conditions are very limited, over the years, the pharmaceutical industry has released a number of treatment offerings to minimize the symptoms of neurodegenerative diseases.
Published Date: 2024-04-25
Pages: 106
USD 4900.00
(Single User License)
Global Rare Neurodegenerative Disease Treatment Market Research Report 2024
Neurodegenerative diseases largely refer to incremental damage to nerve cells in different parts of the body. These ailments, including Alzheimer’s disease, Parkinson’s disease, ADHD, and ALS, can result in loss of memory and cognitive control. While cures for such conditions are very limited, over the years, the pharmaceutical industry has released a number of treatment offerings to minimize the symptoms of neurodegenerative diseases.
Published Date: 2024-02-07
Pages: 91
USD 2900.00
(Single User License)
Rare Neurodegenerative Disease Treatment - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Neurodegenerative diseases largely refer to incremental damage to nerve cells in different parts of the body. These ailments, including Alzheimer’s disease, Parkinson’s disease, ADHD, and ALS, can result in loss of memory and cognitive control. While cures for such conditions are very limited, over the years, the pharmaceutical industry has released a number of treatment offerings to minimize the symptoms of neurodegenerative diseases.
Published Date: 2024-01-11
Pages: 121
USD 3950.00
(Single User License)
Rare Neurodegenerative Disease Treatment- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Rare Neurodegenerative Disease Treatment was estimated to be worth US$ 66140 million in 2025 and is projected to reach US$ 98880 million, growing at a CAGR of 6.0% from 2026 to 2032.
Published: 2026-07-09
Pages: 129
USD 3950.00 (Single User License)Global Rare Neurodegenerative Disease Treatment Market Research Report 2026
The global Rare Neurodegenerative Disease Treatment market was valued at US$ 66140 million in 2025 and is anticipated to reach US$ 98880 million by 2032, at a CAGR of 6.0% from 2026 to 2032.
Published: 2026-04-21
Pages: 116
USD 2900.00 (Single User License)Global Rare Neurodegenerative Disease Treatment Market Outlook, In‑Depth Analysis & Forecast to 2031
The global Rare Neurodegenerative Disease Treatment market is projected to grow from US$ 62750 million in 2024 to US$ 93810 million by 2031, at a CAGR of 6.0% (2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Published: 2025-10-25
Pages: 138
USD 4900.00 (Single User License)Rare Neurodegenerative Disease Treatment- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Rare Neurodegenerative Disease Treatment was estimated to be worth US$ 62750 million in 2024 and is forecast to a readjusted size of US$ 93810 million by 2031 with a CAGR of 6.0% during the forecast period 2025-2031.
Published: 2025-02-21
Pages: 109
USD 3950.00 (Single User License)Global Rare Neurodegenerative Disease Treatment Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Rare Neurodegenerative Disease Treatment market size was US$ 62750 million in 2024 and is forecast to a readjusted size of US$ 93810 million by 2031 with a CAGR of 6.0% during the forecast period 2025-2031.
Published: 2025-02-21
Pages: 77
USD 4250.00 (Single User License)Global Rare Neurodegenerative Disease Treatment Market Insights, Forecast to 2030
Neurodegenerative diseases largely refer to incremental damage to nerve cells in different parts of the body. These ailments, including Alzheimer’s disease, Parkinson’s disease, ADHD, and ALS, can result in loss of memory and cognitive control. While cures for such conditions are very limited, over the years, the pharmaceutical industry has released a number of treatment offerings to minimize the symptoms of neurodegenerative diseases.
Published: 2024-04-25
Pages: 106
USD 4900.00 (Single User License)Global Rare Neurodegenerative Disease Treatment Market Research Report 2024
Neurodegenerative diseases largely refer to incremental damage to nerve cells in different parts of the body. These ailments, including Alzheimer’s disease, Parkinson’s disease, ADHD, and ALS, can result in loss of memory and cognitive control. While cures for such conditions are very limited, over the years, the pharmaceutical industry has released a number of treatment offerings to minimize the symptoms of neurodegenerative diseases.
Published: 2024-02-07
Pages: 91
USD 2900.00 (Single User License)Rare Neurodegenerative Disease Treatment - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Neurodegenerative diseases largely refer to incremental damage to nerve cells in different parts of the body. These ailments, including Alzheimer’s disease, Parkinson’s disease, ADHD, and ALS, can result in loss of memory and cognitive control. While cures for such conditions are very limited, over the years, the pharmaceutical industry has released a number of treatment offerings to minimize the symptoms of neurodegenerative diseases.
Published: 2024-01-11
Pages: 121
USD 3950.00 (Single User License)
USD 2900.00
USD 4350.00
USD 5800.00
Add to Cart
Buy Now
REPORT COVERAGE
DESCRIPTION
OVERVIEW
REPORT SCOPE
QYRESEARCH'S STRENGTHS
TABLE OF CONTENTS
TABLE OF FIGURES
RLEATED REPORTS
INTEREST IN THIS REPORT?
Get A Free Sample
Request For Quotation
OR
NEED A CUSTOMIZED REPORT?
Customized Report
Request Sample
Pre-Order Enquiry
Add to Cart
Buy Now